PROSERA
Are You Eligible?The purpose of this research study is to determine whether seralutanib is safe and effective when given to people with PAH who are already taking other PAH medications.
Research Objectives
Status
Recruitment
Total participants required
Study location
Study type
Patient group
About this clinical trial
Pulmonary Hypertension is a serious condition characterised by high blood pressure in the blood vessels of the lungs. Unlike regular blood pressure measured in the arm, PH refers to the pressure inside the vessels within the lungs, which can only be confirmed through an invasive procedure. This elevated lung pressure causes patients to feel short of breath and, if left untreated, can ultimately lead to right heart failure and death.
While pulmonary hypertension (PH) currently has no cure, early and tailored treatment has been demonstrated to improve disease management and quality of life.
The purpose of this research study is to determine whether seralutanib, an oral inhilation therapy, is safe and effective when given to people with PAH who are already taking other PAH medications.
The treatment is a twice daily inhaler, and the study lasts 52 weeks and includes 14 study visits.
For more information about the clinical trial visit https://clinicaltrials.gov/study/NCT05934526
Prosera
Eligibility
- Patients with Pulmonary artery hypertension
- Aged 18- 75 years
- BMI 17-40
- On stable PAH treatment for past 3 months
Lead investigator
- Dr John Feenstra
Clinical trial coordinator
- Bronwen Field
Technical title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH)
Register your interest
If you would like more information about this clinical trial, please complete the contact form below.